Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2016—Quantimetrix introduced a new formulation for Dip&Spin Urinalysis Dipstick/Microscopics Control. The formulation now features improved crystal sediment components with calcium oxalate dihydrate in their native octahedral morphology and are readily identifiable via standard light microscopy and automated microscopy methods.
March 2016—Advanced Biological Laboratories launched its DeepChek SingleRound HIV and Hepatitis C Virus Genotyping and Sequencing assays. The DeepChek SingleRound HIV RT-PCR and Sequencing Assay detects the major HIV-1 subtypes and combines the reagents (including enzymes) and protocols required to perform the amplification and sequencing of reverse transcriptase, protease, and integrase.
March 2016—ArcherDX, in partnership with Horizon Discovery Group, launched the Archer SureShot ALK, RET, ROS1 Fusion Control to benchmark greater confidence in gene fusion detection using Archer FusionPlex Panels. The reference control is composed of FFPE curls of homogeneously mixed, precisely defined cell lines that contain EML4-ALK, CCDC6-RET, and SLC34A2-ROS1 fusions.
March 2016—Beckman Coulter Diagnostics obtained a CE mark for and released its new Access TSH (3rd IS) assay for use with the company’s Access family of immunoassay systems. This assay is the next generation of the Access Hypersensitive hTSH and Access Fast hTSH assays for the quantitative determination of human thyroid stimulating hormone (TSH, thyrotropin) levels in human serum and plasma.
March 2016—Quest Diagnostics will offer clinical laboratory testing using Dako’s PD-L1 IHC 28-8 pharmDx qualitative test, an FDA-approved complementary in vitro diagnostic test for use in the detection of PD-L1 expression in formalin-fixed, paraffin-embedded melanoma tissue.
March 2016—Bio-Rad Laboratories announced that its D-100 System for A1c testing has obtained FDA clearance to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
February 2016—Foundation Medicine announced a three-way collaboration with Horizon Healthcare Services and Clinical Outcomes Tracking and Analysis to advance precision medicine, improve clinical outcomes, and deliver enhanced value to the health care system in the treatment of patients with metastatic non-small cell lung cancer.
February 2016—Integrated DNA Technologies introduced PrimeTime Gene Expression Master Mix, an optimized enzyme mix for probe-based qPCR. PrimeTime qPCR Assays are available with a choice of dyes and quenchers, and the predesigned assays are backed by a performance guarantee. The Master Mix integrates into new and existing experimental workflows and is also compatible with all commercially available 5’ nuclease gene expression assays.
February 2016—Novogene and Illumina have entered into an agreement to jointly develop advanced clinical applications in the fields of reproductive health and oncology based on next-generation sequencing technology. The companies will work together to develop a user-friendly diagnostic system for clinical prenatal DNA and oncology testing in the Chinese market.
February 2015—PerkinElmer launched its Vectra 3 automated, high-throughput quantitative pathology imaging system. This solution’s new seven-color multiplexing and visualization capabilities are designed to enable pathologists and oncologists conducting research to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches.
